Bharat Biotech has completed the clinical development for phase III trials and booster doses for the intranasal Covid-19 vaccine. Bharat Biotech – the manufacturer of Covid-19 vaccine Covaxin – said that it has completed the clinical development for phase III trials and booster doses for the BBV154 (Covaxin) intranasal Covid-19 vaccine.
The company said that two separate and simultaneous clinical trials were conducted to evaluate BBV154 as a primary dose (2-dose) schedule and a heterologous booster dose for subjects who have previously received 2 doses of the two commonly administered Covid-19 vaccines in India. Data from both Phase III human clinical trials have been submitted for approval to the National Regulatory Authorities, it said. Being an intranasal vaccine, BBV154 may produce local antibodies in the upper respiratory tract, which may provide the potential to reduce infection and transmission.
